.

Is monthly retreatment with intravitreal bevacizumab (Avastin®) necessary in neovascular age-related macular degeneration?

LAUR Repository

Show simple item record

dc.contributor.author Ghazi, Nicola G.
dc.contributor.author Krik, Tyler Q.
dc.contributor.author Knape, Robert M.
dc.contributor.author Tiedeman, James S.
dc.contributor.author Conway, Brian P.
dc.date.accessioned 2019-06-14T10:23:12Z
dc.date.available 2019-06-14T10:23:12Z
dc.date.copyright 2010 en_US
dc.identifier.issn 1177-5483 en_US
dc.identifier.uri http://hdl.handle.net/10725/10823
dc.description.abstract Purpose To report our short-term experience with bevacizumab in neovascular age-related macular degeneration (AMD) and recommend a new treatment strategy. Methods Retrospective chart review of 29 consecutive patients receiving 1.25 mg of intravitreal bevacizumab for AMD and completing 12 weeks of follow up. Outcome measures were best corrected visual acuity (BCVA) and optical coherence tomography (OCT) central macular thickness. Injections were repeated if no further improvement was observed. Results Twenty-nine eyes of 29 patients were included. The average BCVA improved from 20/148 at baseline to 20/106 at twelve weeks (P = 0.041). Of the 29 eyes, 25 (86.2%) had stable or improved BCVA. Average mean central macular thickness measured by OCT improved from 351 μm at baseline to 278 μm at 12 weeks (P = 0.003). Stabilization of vision and improved OCT central macular thickness were maintained for at least eight weeks following only a single injection in the majority of eyes. During the three months of follow up, only five eyes (17.2%) required repeat injections, with only three (10.3%) requiring retreatment at eight weeks and none at four weeks. No significant ocular or systemic side effects were observed. Conclusion This short-term data suggests that bevacizumab appears to be a safe and effective treatment for neovascular AMD. Injections as frequent as every month do not appear to be necessary since initial treatment effect appears to be maintained for at least eight weeks in almost all of our patients. en_US
dc.language.iso en en_US
dc.title Is monthly retreatment with intravitreal bevacizumab (Avastin®) necessary in neovascular age-related macular degeneration? en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOM en_US
dc.author.idnumber 201000154 en_US
dc.author.department N/A en_US
dc.description.embargo N/A en_US
dc.relation.journal Clinical Ophthalmology en_US
dc.journal.volume 4 en_US
dc.article.pages 307 en_US
dc.keywords Retina en_US
dc.keywords Avastin® en_US
dc.keywords Bevacizumab en_US
dc.keywords Neovascular age-related macular degeneration en_US
dc.keywords AMD en_US
dc.identifier.ctation Ghazi, N. G., Kirk, T. Q., Knape, R. M., Tiedeman, J. S., & Conway, B. P. (2010). Is monthly retreatment with intravitreal bevacizumab (Avastin®) necessary in neovascular age-related macular degeneration?. Clinical ophthalmology (Auckland, NZ), 4, 307. en_US
dc.author.email nicola.ghazi@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861937/ en_US
dc.author.affiliation Lebanese American University en_US


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search LAUR


Advanced Search

Browse

My Account